AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
Related topics
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Verogen Partners with QIAGEN to Deliver Innovative Solutions for Human Identification Laboratories

June 29, 2021 GMT

SAN DIEGO & HILDEN, Germany & GERMAN TOWN, Md.--(BUSINESS WIRE)--Jun 29, 2021--

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Prime Standard: QIA) and Verogen Inc. today announced a partnership to provide laboratories with superior tools and comprehensive support for implementing next-generation sequencing (NGS) human identification workflows.

The partnership with QIAGEN is a milestone-driven distribution and development agreement that grants QIAGEN rights to globally distribute both current and future Verogen products. Verogen and QIAGEN will also collaborate to commercialize Verogen’s forensically validated NGS workflows with QIAGEN’s sample prep automation to provide full sample to ID solutions for human identification laboratories.

“Our mission is to empower the human identification community with innovative tools that can deliver an identification, not just a DNA profile,” said Brett Williams, Chief Executive Officer at Verogen. “This partnership with QIAGEN will make it easier for the laboratories to provide more impactful answers. By combining Verogen’s industry-leading NGS-based product portfolio with QIAGEN’s gold-standard extraction, assay, and automation solutions, we can accelerate adoption and utilization of NGS in forensic operations”. “This combination brings together Verogen’s innovative NGS workflows with QIAGEN’s leading portfolio of Sample to Insight solutions, creating the most comprehensive product offering for forensics applications,” said Thierry Bernard, Chief Executive Officer at QIAGEN. “The partnership will drive the adoption of NGS in human identification as it will enable our customers to gain even better insights from their casework samples. This will ultimately strengthen justice systems all over the world.”

ADVERTISEMENT

Verogen’s turnkey solutions for human identification laboratories combine industry-leading NGS sequencing instrumentation, proprietary library prep reagents, and sequencing consumables with sophisticated application-specific software. Through this partnership, QIAGEN will optimize its market-leading sample extraction and library prep automation capabilities for the Verogen ForenSeq ® library prep kits, thereby enhancing both companies’ channel reach and presence to support the forensic market.

About Verogen

ADVERTISEMENT

Verogen is a dedicated developer of DNA-based biometric human identification products for analysis of forensic genomic samples. Working closely with the forensic community, Verogen places exceptional value on flexible, scalable solutions that deliver reliable results. To learn more, visit www.verogen.com

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). Further information can be found at http://www.qiagen.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210629006036/en/

CONTACT: Verogen

Kim Mohr

Insight Communications

949-322-3733

insight.kmohr@gmail.comQIAGEN

Investor Relations

John Gilardi

+49 2103 29 11711Phoebe Loh

+49 2103 29 11457

ir@QIAGEN.comPublic Relations

Thomas Theuringer

+49 2103 29 11826Robert Reitze

+49 2103 29 11676

pr@QIAGEN.com

KEYWORD: CALIFORNIA NETHERLANDS NORTH AMERICA UNITED STATES EUROPE GERMANY

INDUSTRY KEYWORD: SCIENCE OTHER SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL GENERAL HEALTH HEALTH GENETICS

SOURCE: Verogen

Copyright Business Wire 2021.

PUB: 06/29/2021 04:07 PM/DISC: 06/29/2021 04:07 PM

http://www.businesswire.com/news/home/20210629006036/en